NASDAQ:TIL Instil Bio (TIL) Stock Price, News & Analysis $12.85 +1.13 (+9.64%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Instil Bio Stock (NASDAQ:TIL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Instil Bio alerts:Sign Up Key Stats Today's Range$10.80▼$13.5250-Day Range$11.72▼$21.6352-Week Range$9.62▼$92.00Volume298,729 shsAverage Volume129,821 shsMarket Capitalization$84.28 millionP/E RatioN/ADividend YieldN/APrice Target$114.00Consensus RatingBuy Company OverviewInstil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.Read More… Instil Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreTIL MarketRank™: Instil Bio scored higher than 67% of companies evaluated by MarketBeat, and ranked 447th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingInstil Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInstil Bio has only been the subject of 2 research reports in the past 90 days.Read more about Instil Bio's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Instil Bio are expected to grow in the coming year, from ($13.32) to ($11.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Instil Bio is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Instil Bio is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioInstil Bio has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Instil Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.45% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Instil Bio has recently decreased by 2.80%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInstil Bio does not currently pay a dividend.Dividend GrowthInstil Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.45% of the float of Instil Bio has been sold short.Short Interest Ratio / Days to CoverInstil Bio has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Instil Bio has recently decreased by 2.80%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News SentimentN/A News SentimentInstil Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.85 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Instil Bio this week, compared to 0 articles on an average week.Search Interest13 people have searched for TIL on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Instil Bio insiders have not sold or bought any company stock.Percentage Held by Insiders46.50% of the stock of Instil Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.56% of the stock of Instil Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Instil Bio's insider trading history. Receive TIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Instil Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TIL Stock News HeadlinesInstil Bio reports Q4 adjusted EPS ($1.08) vs. ($1.26) last yearMarch 4, 2025 | markets.businessinsider.comInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 4, 2025 | globenewswire.comDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.May 1, 2025 | Weiss Ratings (Ad)Instil Bio: Time To Hop On The Summit Wave?February 24, 2025 | seekingalpha.comPrivate equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as wellFebruary 20, 2025 | finance.yahoo.comJMP Securities Keeps Their Hold Rating on Instil Bio (TIL)February 13, 2025 | markets.businessinsider.comSummit Therapeutics (NASDAQ:SMMT) Stock Quotes, Forecast and News SummaryJanuary 24, 2025 | benzinga.comInstil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific AntibodyJanuary 14, 2025 | globenewswire.comSee More Headlines TIL Stock Analysis - Frequently Asked Questions How have TIL shares performed this year? Instil Bio's stock was trading at $19.09 at the beginning of 2025. Since then, TIL stock has decreased by 32.7% and is now trading at $12.85. View the best growth stocks for 2025 here. How were Instil Bio's earnings last quarter? Instil Bio, Inc. (NASDAQ:TIL) announced its quarterly earnings data on Tuesday, March, 4th. The company reported ($1.82) earnings per share for the quarter, topping the consensus estimate of ($3.75) by $1.93. When did Instil Bio's stock split? Instil Bio's stock reverse split on the morning of Friday, December 8th 2023. The 1-20 reverse split was announced on Friday, December 8th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, December 8th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Instil Bio IPO? Instil Bio (TIL) raised $250 million in an initial public offering on Friday, March 19th 2021. The company issued 13,900,000 shares at $17.00-$19.00 per share. Morgan Stanley, Jefferies, Cowen and Truist Securities acted as the underwriters for the IPO. Who are Instil Bio's major shareholders? Instil Bio's top institutional shareholders include Assenagon Asset Management S.A. (0.81%). View institutional ownership trends. How do I buy shares of Instil Bio? Shares of TIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Instil Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Instil Bio investors own include Tesla (TSLA), CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Taysha Gene Therapies (TSHA), Viking Therapeutics (VKTX), Golden Minerals (AUMN) and Walt Disney (DIS). Company Calendar Last Earnings3/04/2025Today4/30/2025Next Earnings (Estimated)5/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TIL CIK1625584 Webwww.tillcap.com Phone972-499-3350FaxN/AEmployees410Year FoundedN/APrice Target and Rating Average Stock Price Target$114.00 High Stock Price Target$180.00 Low Stock Price Target$52.00 Potential Upside/Downside+787.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($11.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-156,090,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-37.44% Return on Assets-25.08% Debt Debt-to-Equity Ratio0.47 Current Ratio12.90 Quick Ratio12.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$34.72 per share Price / Book0.37Miscellaneous Outstanding Shares6,559,000Free Float3,491,000Market Cap$84.28 million OptionableNo Data Beta1.75 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:TIL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Instil Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Instil Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.